PharmaShots | Incisive News in 3 Shots

Subscribe Now

Agitation

BioXcel Reports the US FDA's Acceptance of BXCL501's NDA for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II

BioXcel Reports the US FDA's Acceptance of BXCL501's NDA for the Acute Treatment of Agitation Associated with Schizophrenia and Bi...

May 19, 2021

BioXcel's BXCL501 Receives the US FDA's Breakthrough Therapy Designation for Acute Treatment of Agitation Associated with Dementia

BioXcel's BXCL501 Receives the US FDA's Breakthrough Therapy Designation for Acute Treatment of Agitation Associated with Dementia

March 15, 2021

Axsome's AXS-05 Receives US FDA's Breakthrough Therapy Designation for the Treatment of Alzheimer's Disease Agitation

Axsome's AXS-05 Receives US FDA's Breakthrough Therapy Designation for the Treatment of Alzheimer's Disease Agitation

June 26, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us